

# Philippe MenaschÃ©

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7106925/publications.pdf>

Version: 2024-02-01

84  
papers

8,521  
citations

94269

37  
h-index

71532

76  
g-index

87  
all docs

87  
docs citations

87  
times ranked

7683  
citing authors

#	ARTICLE	IF	CITATIONS
1	Methods for the identification and characterization of extracellular vesicles in cardiovascular studies: from exosomes to microvesicles. <i>Cardiovascular Research</i> , 2023, 119, 45-63.	1.8	44
2	Dynamic contrast enhanced “ MRI efficiency in detecting embolization-induced perfusion defects in a rabbit model of critical-limb-ischemia. <i>Magnetic Resonance Imaging</i> , 2022, 87, 88-96.	1.0	0
3	Extracellular vesicles from human cardiovascular progenitors trigger a reparative immune response in infarcted hearts. <i>Cardiovascular Research</i> , 2021, 117, 292-307.	1.8	57
4	Insights into therapeutic products, preclinical research models, and clinical trials in cardiac regenerative and reparative medicine: where are we now and the way ahead. Current opinion paper of the ESC Working Group on Cardiovascular Regenerative and Reparative Medicine. <i>Cardiovascular Research</i> , 2021, 117, 1428-1433.	1.8	20
5	Extracellular Vesicles and Biomaterial Design: New Therapies for Cardiac Repair. <i>Trends in Molecular Medicine</i> , 2021, 27, 231-247.	3.5	31
6	Extracellular vesicles can be processed by electrospinning without loss of structure or function. <i>Materials Letters</i> , 2021, 282, 128671.	1.3	7
7	Editorial: Bioengineering and Biotechnology Approaches in Cardiovascular Sciences. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 746435.	2.0	0
8	Development of extracellular vesicle-based medicinal products: A position paper of the group “Extracellular Vesicle translation to clinical perspectives” EVOLVE France. <i>Advanced Drug Delivery Reviews</i> , 2021, 179, 114001.	6.6	42
9	Extracellular vesicles fail to trigger the generation of new cardiomyocytes in chronically infarcted hearts. <i>Theranostics</i> , 2021, 11, 10114-10124.	4.6	10
10	Basic and Translational Research in Cardiac Repair and Regeneration. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2092-2105.	1.2	42
11	In vitro controlled release of extracellular vesicles for cardiac repair from poly(glycerol sebacate) acrylate-based polymers. <i>Acta Biomaterialia</i> , 2020, 115, 92-103.	4.1	18
12	Cell Therapy With Human ESC-Derived Cardiac Cells: Clinical Perspectives. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 601560.	2.0	9
13	Exosomes secreted by hiPSC-derived cardiac cells improve recovery from myocardial infarction in swine. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	112
14	CHIR99021 and fibroblast growth factor 1 enhance the regenerative potency of human cardiac muscle patch after myocardial infarction in mice. <i>Journal of Molecular and Cellular Cardiology</i> , 2020, 141, 1-10.	0.9	40
15	Cardiac cell therapy: Current status, challenges and perspectives. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 285-292.	0.7	18
16	Attrition of the cardiothoracic surgeon-scientist: Definition of the problem and remedial strategies. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 158, 504-508.	0.4	18
17	Transatlantic Editorial: Attrition of the Cardiothoracic Surgeon-Scientist: Definition of the Problem and Remedial Strategies. <i>Annals of Thoracic Surgery</i> , 2019, 108, 315-318.	0.7	6
18	Clinical Translation of Pluripotent Stem Cell Therapies: Challenges and Considerations. <i>Cell Stem Cell</i> , 2019, 25, 594-606.	5.2	53

#	ARTICLE	IF	CITATIONS
19	ESC Working Group on Cellular Biology of the Heart: position paper for Cardiovascular Research: tissue engineering strategies combined with cell therapies for cardiac repair in ischaemic heart disease and heart failure. <i>Cardiovascular Research</i> , 2019, 115, 488-500.	1.8	90
20	Ten-year follow-up of unreplaced Valsalva sinuses after aortic valve replacement in bicuspid aortic valve disease. <i>Archives of Cardiovascular Diseases</i> , 2019, 112, 305-313.	0.7	4
21	Stem cell-derived exosomes and the failing heart: Small cause, big effect. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 156, 1089-1092.	0.4	7
22	Transplantation of Human Embryonic Stem Cell-Derived Cardiovascular Progenitors for Severe Ischemic Left Ventricular Dysfunction. <i>Journal of the American College of Cardiology</i> , 2018, 71, 429-438.	1.2	336
23	Acellular therapeutic approach for heart failure: in vitro production of extracellular vesicles from human cardiovascular progenitors. <i>European Heart Journal</i> , 2018, 39, 1835-1847.	1.0	137
24	Will cardiac surgeons even turn pumpkins into carriages?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 1647-1649.	0.4	0
25	Multiple reoperations on the aortic valve: outcomes and implications for future potential valve-in-valve strategy. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 53, 1251-1257.	0.6	8
26	Platelet vesicles help cardiac stem cells engraft. <i>Nature Biomedical Engineering</i> , 2018, 2, 4-5.	11.6	0
27	Intra-Cardiac Release of Extracellular Vesicles Shapes Inflammation Following Myocardial Infarction. <i>Circulation Research</i> , 2018, 123, 100-106.	2.0	181
28	Evaluation of a new model of hind limb ischemia in rabbits. <i>Journal of Vascular Surgery</i> , 2018, 68, 849-857.	0.6	5
29	Thermoresponsive Gel Embedded with Adipose Stem-Cell-Derived Extracellular Vesicles Promotes Esophageal Fistula Healing in a Thermo-Actuated Delivery Strategy. <i>ACS Nano</i> , 2018, 12, 9800-9814.	7.3	60
30	Long-Term Engraftment (16 Years) of Myoblasts in a Human Infarcted Heart. <i>Stem Cells Translational Medicine</i> , 2018, 7, 705-708.	1.6	9
31	Experimental Evaluation of Endovascular Fenestration Scissors in an Ovine Model of Aortic Dissection. <i>European Journal of Vascular and Endovascular Surgery</i> , 2018, 56, 373-380.	0.8	3
32	Cell therapy trials for heart regeneration – lessons learned and future directions. <i>Nature Reviews Cardiology</i> , 2018, 15, 659-671.	6.1	200
33	Vésicules extra cellulaires : nouveaux agents thérapeutiques pour la réparation cardiaque ?. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2018, 202, 755-769.	0.0	0
34	HEMO-2 life as a protective additive to Celsior solution for static storage of donor hearts prior to transplantation. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2017, 45, 717-722.	1.9	27
35	A 3D magnetic tissue stretcher for remote mechanical control of embryonic stem cell differentiation. <i>Nature Communications</i> , 2017, 8, 400.	5.8	123
36	Do not throw the baby with the water bath!. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 154, 557.	0.4	0

#	ARTICLE	IF	CITATIONS
37	Effect of Levosimendan on Low Cardiac Output Syndrome in Patients With Low Ejection Fraction Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 548.	3.8	143
38	Building a bioartificial heart: A 3-song saga. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 153, 744-747.	0.4	0
39	Fibers for hearts: A critical review on electrospinning for cardiac tissue engineering. <i>Acta Biomaterialia</i> , 2017, 48, 20-40.	4.1	230
40	Global position paper on cardiovascular regenerative medicine. <i>European Heart Journal</i> , 2017, 38, 2532-2546.	1.0	133
41	The future of stem cells: Should we keep the "stem" and skip the "cells"? <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 152, 345-349.	0.4	8
42	CD133+ cells: How could they have an IMPACT?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 152, 1589-1591.	0.4	2
43	Rationale and design of the multicenter randomized trial investigating the effects of levosimendan pretreatment in patients with low ejection fraction ( $\leq 40\%$ ) undergoing CABG with cardiopulmonary bypass (LICORN study). <i>Journal of Cardiothoracic Surgery</i> , 2016, 11, 127.	0.4	12
44	Mast cells regulate myofilament calcium sensitization and heart function after myocardial infarction. <i>Journal of Experimental Medicine</i> , 2016, 213, 1353-1374.	4.2	97
45	Cardiovascular progenitor-derived extracellular vesicles recapitulate the beneficial effects of their parent cells in the treatment of chronic heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 795-807.	0.3	161
46	Nanofibrous clinical-grade collagen scaffolds seeded with human cardiomyocytes induces cardiac remodeling in dilated cardiomyopathy. <i>Biomaterials</i> , 2016, 80, 157-168.	5.7	65
47	Inhibition of factor IXa by the pegnivacogin system during cardiopulmonary bypass: a potential substitute for heparin. A study in baboons. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 49, 682-689.	0.6	11
48	Comparative Analysis of Methods to Induce Myocardial Infarction in a Closed-Chest Rabbit Model. <i>BioMed Research International</i> , 2015, 2015, 1-9.	0.9	9
49	Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report: Figure 1. <i>European Heart Journal</i> , 2015, 36, 2011-2017.	1.0	383
50	The Evolution of the Stem Cell Theory for Heart Failure. <i>EBioMedicine</i> , 2015, 2, 1871-1879.	2.7	24
51	Long-term functional benefits of human embryonic stem cell-derived cardiac progenitors embedded into a fibrin scaffold. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 1198-1207.	0.3	80
52	Fabrication of cardiac patch by using electrospun collagen fibers. <i>Microelectronic Engineering</i> , 2015, 144, 46-50.	1.1	37
53	Polymer-Based Reconstruction of the Inferior Vena Cava in Rat: Stem Cells or RGD Peptide?. <i>Tissue Engineering - Part A</i> , 2015, 21, 1552-1564.	1.6	21
54	Stem cells in the management of advanced heart failure. <i>Current Opinion in Cardiology</i> , 2015, 30, 179-185.	0.8	9

#	ARTICLE	IF	CITATIONS
55	Stem cells for the treatment of heart failure. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2015, 370, 20140373.	1.8	6
56	Towards a clinical use of human embryonic stem cell-derived cardiac progenitors: a translational experience. <i>European Heart Journal</i> , 2015, 36, 743-750.	1.0	137
57	Effect of severe acidosis on vasoactive effects of epinephrine and norepinephrine in human distal mammary artery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 147, 1698-1705.	0.4	7
58	How Close Are We to Using Stem Cells in Routine Cardiac Therapy?. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1265-1269.	0.8	2
59	Editorial Comment: Adenosine in heart transplants: have we finally found the good indication?. <i>European Journal of Cardio-thoracic Surgery</i> , 2013, 43, 1209-1210.	0.6	0
60	Can Magnetic Targeting of Magnetically Labeled Circulating Cells Optimize Intramyocardial Cell Retention?. <i>Cell Transplantation</i> , 2012, 21, 679-691.	1.2	41
61	Stem cell therapy for chronic heart failure. Lessons from a 15-year experience. <i>Comptes Rendus - Biologies</i> , 2011, 334, 489-496.	0.1	19
62	Cardiac cell therapy: Lessons from clinical trials. <i>Journal of Molecular and Cellular Cardiology</i> , 2011, 50, 258-265.	0.9	153
63	Recommendations for Successful Training on Methods of Delivery of Biologics for Cardiac Regeneration. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 265-275.	1.1	71
64	A polydioxanone electrospun valved patch to replace the right ventricular outflow tract in a growing lamb model. <i>Biomaterials</i> , 2010, 31, 4056-4063.	5.7	50
65	A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. <i>Journal of Clinical Investigation</i> , 2010, 120, 1125-1139.	3.9	287
66	Cell therapy for peripheral arterial disease. <i>Current Opinion in Molecular Therapeutics</i> , 2010, 12, 538-45.	2.8	10
67	Stem Cell Therapy for Heart Failure. <i>Circulation</i> , 2009, 119, 2735-2740.	1.6	122
68	Cell Delivery: Intramyocardial Injections or Epicardial Deposition? A Head-to-Head Comparison. <i>Annals of Thoracic Surgery</i> , 2009, 87, 1196-1203.	0.7	112
69	Cell-based Therapy for Heart Disease: A Clinically Oriented Perspective. <i>Molecular Therapy</i> , 2009, 17, 758-766.	3.7	63
70	Cardiac Cell Therapy Trials: Chronic Myocardial Infarction and Congestive Heart Failure. <i>Journal of Cardiovascular Translational Research</i> , 2008, 1, 201-206.	1.1	10
71	Characterization of the paracrine effects of human skeletal myoblasts transplanted in infarcted myocardium. <i>European Journal of Heart Failure</i> , 2008, 10, 1065-1072.	2.9	119
72	The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) Trial. <i>Circulation</i> , 2008, 117, 1189-1200.	1.6	878

#	ARTICLE	IF	CITATIONS
73	Current Status and Future Prospects for Cell Transplantation to Prevent Congestive Heart Failure. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2008, 20, 131-137.	0.4	43
74	Skeletal Myoblasts Preserve Remote Matrix Architecture and Global Function When Implanted Early or Late After Coronary Ligation Into Infarcted or Remote Myocardium. <i>Circulation</i> , 2008, 118, S130-S137.	1.6	57
75	Challenging the Cardiac Differentiation of Bone Marrow Cells: A Clinical Perspective. <i>Molecular Therapy</i> , 2008, 16, 1000-1001.	3.7	6
76	Skeletal Myoblast Transplantation for Ischemic Heart Failure. , 2008, , 189-202.		0
77	Cellular Therapy in Thoracic and Cardiovascular Disease. <i>Annals of Thoracic Surgery</i> , 2007, 84, 339-342.	0.7	2
78	Skeletal Myoblasts as a Therapeutic Agent. <i>Progress in Cardiovascular Diseases</i> , 2007, 50, 7-17.	1.6	129
79	Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1078-1083.	1.2	1,072
80	Viability and differentiation of autologous skeletal myoblast grafts in ischaemic cardiomyopathy. <i>Lancet, The</i> , 2003, 361, 491-492.	6.3	265
81	Myoblasts transplanted into rat infarcted myocardium are functionally isolated from their host. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 7808-7811.	3.3	466
82	Cell transplantation for the treatment of heart failure. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2002, 14, 157-166.	0.4	38
83	Long-term efficacy of myoblast transplantation on regional structure and function after myocardial infarction. <i>Circulation</i> , 2002, 106, I131-6.	1.6	144
84	Myoblast transplantation for heart failure. <i>Lancet, The</i> , 2001, 357, 279-280.	6.3	1,044